Treatment of oppositional defiant disorder and conduct...

Details Treatment of oppositional defiant disorder and conduct... Treatment of oppositional defiant disorder and conduct...

2005-05-24

2005-05-24

Henley, III, Raymond J. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S412000

Reexamination Certificate

active

06897212

ABSTRACT:
A method for treating the psychiatric disorders known as oppositional defiant disorder and conduct disorder is disclosed. The method comprises the administration of a compound according to Formula I or II to a patient suffering from oppositional defiant disorder and/or conduct disorder. The compound may be either a racemic mixture or e.g. the levorotatory form. It may be short acting or in a sustained release, long acting form. Molindone or a pharmaceutically acceptable salt of molindone is a preferred embodiment.

REFERENCES:
patent: 3491093 (1970-01-01), Pachter
patent: 4065453 (1977-12-01), Finizio
patent: 5663167 (1997-09-01), Pickar et al.
patent: 6028070 (2000-02-01), Heiligenstein
patent: 6090829 (2000-07-01), Bodick et al.
patent: 6136824 (2000-10-01), MacLeod et al.
patent: 6184222 (2001-02-01), Heiligenstein
patent: 6210950 (2001-04-01), Johnson et al.
patent: 6214846 (2001-04-01), Elliott
patent: 6613763 (2003-09-01), Comings et al.
Greenhill et al. J. Clin. Psychiatry, (Aug. 1985), 46 (8 Pt. 2) pp 20-25 Abstract Only.*
S. Leucht et al., “Therapeutics Review: in people wit schizophrenia, lithium is ineffective.,” Evidence-Based Mental Health, 2004; 7: 104. EMBH Online.
S. Leucht et al., “Lithium for schizophrenia (Cochrane Review),” The Cochrane Library, Issue 4, 2004. ABSTRACT.
Dr. Joseph F. Smith Medical Library, Delusions. (2004).
Physicians' Desk Reference, Edition 55, 2001. Lithium Carbonate, p. 2827.
Ravina, Enrique et al., “Conformationally constrained butyrophenones. . . ,” Current Medicinal Chemistry—Central Nervous System Agents, May 2001, vol. 1, No. 1, pp. 43-62.
Laurence L. Greenhill et al., “Molindone Hydrochloride in the treatment of aggressive, hospitalized children,” pp. 125-127. XP008019356. (no date available).
Laurence L. Greenhill et al., “Molindone Hydrochloride in the treatment of hospitalized children with conduct disorder,” J.Clin.Psychiatry, Aug. 1985, 46 : 8 (Sec. 2), pp. 20-25. XP008019351.
Richard R. Owen et al., “Molindone Hydrochloride: A review of laboratory and clinical findings,” J. Clin. Pyschopharmacology, Aug. 1989, vol. 9, No. 4. pp. 268-276.
Priscille Gerardin et al., “Drug treatment of conduct disorder in young people,” European Neuropsychopharmacology, 2002, vol. 12, pp. 361-370. XP-002246780.
“Letters to the Editor,” J.Am.Acad.Child Adolesc. Psychiatry, Jan. 1997, 36:1, pp. 1-3. XP008019353.
Elizabeth B. Weller, M.D. et al., “Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive development disorders,” J.Clin. Psychiatry, 1999, 60 (suppl 15), pp. 5-11. XP008019349.

Affiliated with

Also associated with

Rating

Treatment of oppositional defiant disorder and conduct... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of oppositional defiant disorder and conduct..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of oppositional defiant disorder and conduct... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3441821